The French General Directorate for Food (DGAL) has implemented a ban on the sale of CBD-infused edibles, effective May 15. This measure, which impacts products such as gummies, tinctures, and supplements, represents a stricter enforcement of the European Union’s 1997 food safety regulation concerning novel foods. The decision directly affects the market for French CBD edibles regulation, which previously saw these products widely available in retail channels across France.
Enforcement of EU Novel Food Regulation and Market Impact
The ban stems from the EU’s 1997 food safety regulation concerning novel foods and novel food ingredients, which mandates pre-market authorisation for any food product not extensively consumed in the EU prior to that regulation. Cannabidiol (CBD) and its derived products, when intended for ingestion, are classified as novel foods under this framework. Consequently, they require a specific authorisation process from the European Commission, a process that many existing CBD edible products have not completed. The DGAL announced this enforcement last month, as reported by Ganjapreneur, building on earlier indications of stricter oversight, as previously reported by Hemp Gazette.
Prior to this enforcement, CBD-infused consumables constituted a significant segment of the French hemp product market. According to the Ganjapreneur report, these edibles accounted for approximately 40% of total hemp product sales in France. This substantial market share indicates the commercial impact of the DGAL’s decision on retailers and manufacturers. The ban specifically targets ingestible CBD products, including those marketed as food supplements, and does not extend to other hemp-derived items such as hemp flower or vaporizers, which fall under different regulatory classifications.
The distinction in regulatory treatment between ingestible and non-ingestible CBD products highlights the specific focus on food safety and consumer protection within the novel food framework. Companies that have invested in the production and distribution of CBD edibles must now either cease sales of these products or pursue the novel food authorisation process.
Industry Response and Regulatory Landscape
The industry response to the ban on French CBD edibles regulation has included expressions of concern regarding its scope and perceived inconsistency. Paul Maclean, a representative of the UPCBD trade association, stated via AFP that the decision to target only edibles was “completely absurd,” questioning the rationale behind the selective enforcement when other CBD product forms remain available. This regulatory shift creates an immediate challenge for businesses that relied on the sale of CBD-infused food products, requiring them to adjust their product offerings, supply chains, and market strategies to comply with the new directive.
The enforcement underscores the ongoing regulatory complexities surrounding CBD products within the European Union. While some member states have adopted more permissive approaches or are in various stages of developing specific CBD regulations, France’s move highlights a stricter interpretation of existing EU food safety frameworks. This fragmentation means that companies operating in the European CBD market must navigate a diverse regulatory landscape, where national interpretations of EU directives can lead to significant variations in product availability and market access across different countries. The lack of a harmonised EU-wide approach to CBD classification and regulation continues to pose challenges for businesses seeking to operate across borders.
Broader French Cannabis Policy Context
In parallel with the restrictions on French CBD edibles, France’s medical cannabis framework remains limited. The country is currently operating under a recently extended pilot program for medical cannabis. Discussions are ongoing regarding potential broader national reforms for medical cannabis, with indications that a more permanent framework could materialise in early 2027. This demonstrates a gradual, controlled approach to cannabis-related policies within the nation. The DGAL’s action on CBD edibles reflects a consistent regulatory posture that prioritises established food safety protocols and controlled access pathways for cannabis-derived compounds, whether for general consumption or medical use.
The French government’s stance aligns with a broader trend among some European regulators to tighten controls on CBD products, particularly those ingested, until comprehensive scientific data and regulatory frameworks are in place to ensure consumer safety and product quality. This approach contrasts with the rapid expansion of the CBD market in other regions and highlights the cautious regulatory environment for novel food ingredients in France.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
